Europe Cancer Vaccines Market is segmented by Technology, Treatment Method (Preventive Vaccine and Therapeutic Vaccine), Application and Geography.

The value of the European mRNA combined vaccines and therapies market is forecast to reach around **** billion U.S. dollars by the end of 2030. In 2020, the market was estimated at approximately *** billion U.S. dollars. This would represent a compound annual growth rate of just over eight percent between 2020 and 2030. More information on the global mRNA vaccines and therapies market can be found here.

The global travel vaccines market, valued at $5 billion in 2025, is projected to experience robust growth, driven by rising international travel, increasing awareness of vaccine-preventable diseases, and government initiatives promoting vaccination. The market's Compound Annual Growth Rate (CAGR) of 8.33% from 2025 to 2033 indicates a significant expansion, reaching an estimated $9.5 billion by 2033. Key drivers include the increasing prevalence of vaccine-preventable diseases in various regions, particularly in developing countries, alongside enhanced tourism infrastructure facilitating easier and more frequent global travel. Growth is further fueled by the development of novel vaccines, improved cold chain logistics for vaccine distribution, and increased public-private partnerships focused on vaccine accessibility and affordability. However, factors like high vaccine costs, vaccine hesitancy in certain demographics, and potential adverse reactions to certain vaccines pose challenges to market growth. The market is segmented by vaccine type (Cholera, DPT, Encephalitis, Hepatitis A, Meningococcal, Rabies, Typhoid, Yellow Fever, and others), travel type (domestic and outbound), and vaccination centers (hospitals, travel clinics, and others). Geographic segmentation reveals significant regional variations in market size and growth potential, with North America and Europe holding substantial market shares due to higher disposable incomes and advanced healthcare infrastructure. Asia-Pacific is expected to show significant growth driven by increasing travel and rising disposable incomes in several countries within the region. The competitive landscape is marked by the presence of major pharmaceutical companies such as Abbott Laboratories, AstraZeneca, CSL, Roche, GSK, Janssen, Pfizer, Qiagen, Sanofi, and Valneva, among others. These players are continuously investing in research and development to introduce innovative vaccines and expand their geographic reach. Strategic alliances, mergers, and acquisitions are expected to shape the market dynamics in the coming years. The future of the travel vaccines market hinges on overcoming challenges related to vaccine accessibility and affordability in developing nations, enhancing vaccine safety profiles, and addressing vaccine hesitancy through effective public health campaigns. The focus on personalized medicine and the development of combination vaccines offering protection against multiple diseases are key trends shaping the market's future trajectory. This comprehensive report provides a detailed analysis of the global travel vaccines market, covering the period from 2019 to 2033. It offers in-depth insights into market size, growth drivers, challenges, trends, and competitive landscape, equipping stakeholders with the knowledge needed to navigate this dynamic sector. The report utilizes data from the historical period (2019-2024), base year (2025), and estimated year (2025) to project market trends until 2033. Recent developments include: March 2024: The UAE Ministry of Health and Prevention (MoHAP) mandated influenza vaccination for pilgrims traveling to Saudi Arabia. It was a preventive measure to protect the Hajj performers, their families, and all segments of society from infectious diseases., February 2024: The University of Kentucky’s UK Retail Pharmacies started offering travelers all the required and recommended vaccines based on their destination, including yellow fever, typhoid, and cholera., May 2023: Bavarian Nordic acquired Emergent BioSolutions’ travel vaccine portfolio for USD 274 million. The deal encompassed the acquisition of vaccines Vivotif and Vaxchora, marketed for the prevention of typhoid and cholera, respectively, and a phase III vaccine candidate for the prevention of the chikungunya virus.. Key drivers for this market are: Significant Rise in Outbound Tourism, Prevalence of Hepatitis A Across Most Travelled Destinations; Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations. Potential restraints include: Significant Rise in Outbound Tourism, Prevalence of Hepatitis A Across Most Travelled Destinations; Increasing Meetings, Incentives, Conferences, and Exhibitions (MICE) in Different Nations. Notable trends are: The Hepatitis A Segment is Expected to Witness Significant Growth During the Forecast Period.

The Market Report Covers Europe Veterinary Vaccine Manufacturers and is Segmented by Animal Vaccine Type (Livestock Vaccines and Companion Animal Vaccines), Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Technologies), and Geography (Germany, United Kingdom, France, Italy, Spain and Rest of Europe). The value is provided in (USD million) for the above segments.

The Europe Veterinary Vaccine Market is projected to grow at a CAGR of around 5.5% during the forecast period 2021-2026 says- MarkNtel Advisors.

Europe Chicken Vaccines accounted for a share of over 30% of the global market size of USD XX million in 2023 and projected to expand at a CAGR of 6.5% from 2023 to 2030.

Snapshot img

Vaccines Market Size 2025-2029

The vaccines market size is forecast to increase by USD 160.22 billion at a CAGR of 23.1% between 2024 and 2029.

The market is experiencing significant growth, driven by increased funding for research and development, leading to the launch of new vaccines. One of the most promising trends in this market is the development of nanoparticle vaccines, which offer enhanced immunogenicity and improved delivery systems. This trend is particularly evident in the development of nanoparticle vaccines, which offer enhanced efficacy and safety. However, the high cost of research, development, and manufacturing poses a significant challenge for market players. Examples include the inactivated polio vaccine (IPV) and influenza vaccine. These costs can be attributed to the complex production processes involved in vaccine creation, as well as the need for rigorous clinical trials to ensure safety and efficacy. 
However, the high cost of vaccine research, development, and manufacturing remains a significant challenge for market participants. Despite this, the market presents numerous opportunities for companies seeking to capitalize on the growing demand for vaccines, particularly in emerging economies with rising healthcare expenditures. Strategic partnerships, collaborations, and acquisitions are key strategies for companies looking to navigate the competitive landscape and stay ahead of the curve.
Overall, the market is poised for continued growth, with significant opportunities for innovation and investment in the coming years. Companies that can effectively address the challenges of cost and regulatory compliance while delivering high-quality, effective vaccines will be well-positioned to succeed.

What will be the Size of the Vaccines Market during the forecast period?

Request Free Sample

The market driven by the continuous development of immunization programs and the pursuit of vaccine equity. Immunological memory, antibody response, and cost-effectiveness analysis are key factors influencing market growth. Vaccine supply chain, efficacy testing, preservation, patent, and licensing are essential aspects of the market. Nanotechnology and universal vaccines are emerging trends, aiming to improve vaccine accessibility and quality control. Vaccine manufacturing, regulatory approval, and economic impact are crucial elements in the market, with intellectual property, vaccine shelf life, and vaccine development pipeline being significant factors.
Vaccine innovation and vaccine safety monitoring are essential for addressing disease burden and ensuring potency, stability, and sterility. Vaccine logistics and vaccine stability are critical for successful distribution and administration, while vaccine safety monitoring emphasizes the importance of ongoing surveillance and immune response assessment. 

How is this Vaccines Industry segmented?

The vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Subunit vaccines
  Live attenuated vaccines
  Inactivated vaccines
  Toxoid vaccines
  Others


End-user

  Hospitals
  Clinics


Technology

  mRNA vaccines
  Viral vector vaccines
  Protein based vaccines
  DNA vaccines
  Others


Route Of Administration

  Intramuscular
  Subcutaneous
  Oral
  Intranasal
  Others


Disease Type

  Influenza
  Human papillomavirus
  Hepatitis
  Measles
  mumps
  rubella
  Others


Age Group

  Pediatric
  Adult
  Adolescent
  Geriatric


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The subunit vaccines segment is estimated to witness significant growth during the forecast period.

Subunit vaccines, integral components of the healthcare system's disease prevention strategy, employ specific antigenic pieces of a pathogen, such as proteins, sugars, or capsids, to induce a robust immune response. These vaccines, including the mRNA vaccines, are designed to target specific components of the pathogen, making them highly effective in preventing infections. The development process involves identifying and isolating these antigenic components, followed by formulation and rigorous testing to ensure safety and efficacy. For instance, in the realm of disease outbreak prevention, a phase 3 trial for the subunit TB vaccine candidate M72/AS01E was initiated in March 2024 in South Africa.

This trial aims to evaluate the vaccine's efficacy in preventing the progression from latent TB to active pulmonary TB, contributing to herd immunity and ultimately, disease surveillance and vaccine distribution within the healthcare s

The Eastern Europe Vaccines market report offers a thorough competitive analysis, mapping key players’ strategies, market share, and business models. It provides insights into competitor dynamics, helping companies align their strategies with the current market landscape and future trends.

The European market for vaccines in human medicine is expected to see continued growth over the next decade, driven by increasing demand. Market performance is forecasted to accelerate, with a projected CAGR of +2.8% in volume terms, reaching 37K tons by 2035. In value terms, the market is anticipated to increase at a CAGR of +3.9%, reaching $53.9B by the end of 2035.

Access Europe Pneumococcal Vaccines Industry Overview which includes Europe country analysis of (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe), market split by Vaccine Type, Product Type, Sector, Distribution Channel

The global childhood vaccines market is a significant and rapidly expanding sector, projected to experience substantial growth over the forecast period (2025-2033). While precise market size figures for 2019-2024 are unavailable, we can infer substantial growth based on the presence of major pharmaceutical players like GSK, Sanofi, Pfizer, and Merck, coupled with increasing global vaccination initiatives. The market is driven by rising awareness of vaccine-preventable diseases, stringent government regulations mandating childhood vaccinations, and the continuous development of advanced vaccine technologies such as recombinant and viral vaccines. Furthermore, the increasing prevalence of vaccine-preventable diseases in developing economies fuels market expansion. However, factors such as vaccine hesitancy, adverse effects concerns, and high vaccine costs pose challenges to market growth. The market is segmented by application (hospital, clinic) and vaccine type (recombinant, viral, polysaccharide, and others). Recombinant and viral vaccines are expected to dominate owing to their effectiveness and safety profile. Geographically, North America and Europe currently hold significant market shares due to advanced healthcare infrastructure and high vaccination rates. However, Asia Pacific is projected to witness the fastest growth due to rising disposable incomes, improving healthcare infrastructure, and increasing government initiatives promoting vaccination programs. The competitive landscape is characterized by the presence of both multinational pharmaceutical giants and regional players. Future growth will be driven by ongoing research and development into new and improved vaccines, coupled with increasing public-private partnerships focused on expanding vaccination access in underserved regions. The continued expansion of the childhood vaccines market is underpinned by a confluence of factors. Governmental support through robust immunization programs, coupled with ongoing investment in vaccine R&D, is a crucial element. This includes not only developing new vaccines but also improving existing ones to increase efficacy and safety. The market's segmentation reflects the diversity of approaches to immunization. The success of specific vaccine types (such as recombinant and viral vaccines) will depend on their ability to address emerging disease strains and public health concerns. Regional variations will continue, reflecting both economic development levels and the prevalence of specific infectious diseases. Consequently, the forecast for continued growth is strong, but challenges remain, emphasizing the importance of public health education and collaborative strategies to enhance vaccine uptake and combat vaccine hesitancy.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

The Europe Pneumococcal Vaccine Market size will exceed a valuation of USD 13.34 billion by 2032, to grow at a CAGR of 5.7% during the forecast period.

In Europe Aquaculture Vaccines Market, offering valuable insights, key market trends, competitive landscape, and future outlook to support strategic decision.

The Europe Rabies Vaccine Market would witness market growth of 4.1% CAGR during the forecast period (2023-2030). The Germany market dominated the Europe Rabies Vaccine Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $101 Millio

Snapshot img

Human Combination Vaccines Market Size 2025-2029

The human combination vaccines market size is forecast to increase by USD 7.72 billion, at a CAGR of 8.8% between 2024 and 2029.

The market is characterized by significant growth opportunities and challenges. Key drivers include the increasing prevalence of infectious diseases and the growing awareness of the importance of vaccination in preventing them. However, the market also faces challenges, including the rising threat of antiviral drug resistance, which can reduce the effectiveness of some vaccines. Furthermore, the threat from bioterrorism has led to an increased focus on developing combination vaccines that can protect against multiple diseases simultaneously. Consolidation of different immunization schedules is another trend shaping the market, as healthcare providers seek to simplify vaccine administration and improve patient compliance. Companies in this market must navigate these challenges while capitalizing on the growing demand for combination vaccines to remain competitive and succeed. Effective strategies may include investing in research and development of new combination vaccines, expanding production capacity, and collaborating with healthcare providers to streamline immunization schedules. By addressing these challenges and leveraging market opportunities, companies can position themselves for long-term success in the market.

What will be the Size of the Human Combination Vaccines Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free SampleThe market continues to evolve, driven by the ongoing development of new technologies and applications across various sectors. Pneumococcal disease remains a significant focus, with research and innovation centered around pneumococcal conjugate vaccines, inactivated vaccines, and polysaccharide vaccines. The use of viral vectors, needle-free injection, and immunization programs is expanding, enhancing vaccine access and effectiveness. Market dynamics are shaped by factors such as regulatory approvals, cold chain management, and immunization schedules. Pharmaceutical companies are investing in peptide vaccines, t-cell response, and DNA vaccines, aiming to improve vaccine efficacy and healthcare costs. Market access remains a critical concern, with efforts to address vaccine hesitancy and ensure equitable distribution. The manufacturing process, quality control, and vaccine shelf life are essential considerations, with ongoing research into vaccine delivery systems, recombinant vaccines, and MRNA technology. Health outcomes and healthcare costs are under constant scrutiny, with global health initiatives and vaccination rates playing a crucial role in disease prevention and pandemic preparedness. Vaccine development pipelines are continually evolving, with clinical trials exploring the potential of new adjuvants, vaccine adjuvants, and vaccine effectiveness. The role of intellectual property, disease surveillance, and antibody response in shaping the market landscape is an ongoing discussion. The market's continuous dynamism underscores the importance of staying informed about the latest trends and developments.

How is this Human Combination Vaccines Industry segmented?

The human combination vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. TypeInactivated vaccineLive attenuated vaccineChannelHospitalsRetailersOnlineRoute Of AdministrationIntramuscularSubcutaneousOralIntradermalNasal sprayGeographyNorth AmericaUSCanadaMexicoEuropeFranceGermanyItalyUKAPACChinaIndiaJapanRest of World (ROW)

By Type Insights

The inactivated vaccine segment is estimated to witness significant growth during the forecast period.The market encompasses a range of vaccine types, including inactivated, live-attenuated, subunit, conjugate, recombinant, peptide, and DNA vaccines. Inactivated vaccines, which account for the largest market share, utilize a process where pathogen particles are destroyed or killed, ensuring they cannot replicate. This segment's dominance is attributed to their better tolerability and fewer complications when combining different antigens. However, producing combination vaccines poses challenges due to potential incompatibilities and interactions among various components. Public awareness campaigns and regulatory approvals play a crucial role in driving the market, with a focus on pandemic preparedness and disease prevention. Vaccine packaging, cold chain management, and storage and stability are essential considerations to maintain vaccine efficacy. Clinical trials, vaccine delivery systems, and quality control are integral parts of the vaccin

The Europe Ruminant Vaccines Market would witness market growth of 6.3% CAGR during the forecast period (2024-2031). The Germany market dominated the Europe Ruminant Vaccines Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $331.1

The global vaccines market, valued at $61.89 billion in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 13.83% from 2025 to 2033. This expansion is driven by several key factors. Firstly, increasing government initiatives promoting vaccination programs globally, particularly in developing nations, are significantly boosting market demand. Secondly, the rising prevalence of vaccine-preventable diseases and the emergence of new infectious agents necessitates continuous vaccine development and deployment. The market also benefits from advancements in vaccine technology, leading to the development of more effective, safer, and convenient vaccines, including mRNA vaccines. Furthermore, the growing awareness among consumers regarding the importance of vaccination for personal and public health contributes significantly to market growth. The market is segmented into human and animal vaccines, with the human vaccine segment likely holding a larger share due to the higher prevalence of vaccine-preventable diseases in humans and increased investment in research and development. Competition in the market is intense, with major players like Pfizer, Johnson & Johnson, Sanofi, and Merck & Co. employing various strategies such as mergers and acquisitions, strategic partnerships, and extensive research and development efforts to maintain their market positions. Geographic variations exist, with North America and Europe expected to dominate the market initially, followed by strong growth in Asia-Pacific regions due to rising disposable incomes and increasing healthcare expenditure. However, market growth faces certain challenges. High vaccine development costs, stringent regulatory approvals, and the potential for adverse reactions can hinder market expansion. Furthermore, vaccine hesitancy and misinformation pose significant hurdles to achieving widespread vaccination coverage. Despite these challenges, the long-term outlook for the vaccines market remains positive, driven by the persistent threat of infectious diseases, continuous technological advancements, and sustained investment in vaccination programs. The market’s continued growth relies heavily on effectively addressing vaccine hesitancy through public health initiatives, transparent communication, and rigorous safety monitoring. The diversification of vaccine types, such as the growth of mRNA technology, also contributes to market expansion as new and improved vaccines are introduced.

The global vaccines market exhibits robust growth, driven by increasing disease prevalence, rising vaccination rates, and continuous technological advancements in vaccine development. The market's expansion is fueled by several key factors. Firstly, the heightened awareness of preventable diseases and the associated health risks are prompting governments and healthcare organizations to implement comprehensive vaccination programs globally. Secondly, the emergence of novel vaccines, such as mRNA vaccines, has significantly broadened the scope of vaccine applications and improved efficacy. Thirdly, the continuous research and development efforts aimed at creating more effective and safer vaccines, particularly for challenging diseases like influenza and HIV, contribute to the market's dynamic growth. While the market faces challenges like vaccine hesitancy and supply chain complexities in certain regions, the overall trajectory remains positive, with a projected substantial increase in market value over the forecast period. Specific segments, such as recombinant and viral vaccines, are expected to witness particularly rapid growth, driven by their higher efficacy and safety profiles compared to traditional vaccines. Geographic variations exist, with North America and Europe currently dominating the market, while Asia-Pacific is projected to exhibit significant growth in the coming years due to rising disposable incomes and improved healthcare infrastructure. The competitive landscape comprises major pharmaceutical companies alongside emerging players, fostering innovation and driving further market expansion. The market segmentation by application reveals a diverse portfolio of vaccines addressing various infectious diseases. Rabies, influenza, HPV, and Hepatitis vaccines represent significant portions of the market, reflecting the prevalence and impact of these diseases globally. However, the market also sees significant investment in vaccines for less prevalent yet equally important diseases, such as leprosy and JE. The segment based on vaccine type showcases the evolution of vaccine technology, with recombinant and viral vaccines leading the innovation and growth. This shift signifies a transition towards more effective, targeted, and safer vaccine options. The regional breakdown highlights the established dominance of developed markets but also emphasizes the significant growth potential of emerging economies, particularly in Asia-Pacific, driven by increasing populations, improving healthcare access and government-sponsored vaccination programs. This diverse landscape ensures the vaccines market remains a dynamic and promising sector with significant implications for global public health.

Europe Human Papillomavirus Vaccine market will be USD 1297.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.7% from 2024 to 2031. Increasing prevalence of sexually transmitted infections (STIs) is expected to aid the sales to USD 2925.8 million by 2031